No Link Seen Between Exposure to Immunosuppressive Therapy, Cancer in IBD Patients
By Elana Gotkine HealthDay Reporter
TUESDAY, June 11, 2024 -- There is no significant association between exposure to immunosuppressive therapies and development of incident cancers among patients with inflammatory bowel disease (IBD) and a history of cancer, according to a study published online May 18 in Clinical Gastroenterology and Hepatology.
Steven H. Itzkowitz, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues followed 305 patients with IBD and confirmed index cancer prior to enrollment. Index cancers were solid organ, dermatologic, gastrointestinal, and hematologic (46, 32, 13, and 9 percent, respectively).
The researchers found that 69 percent of patients were exposed to immunosuppressive therapy during a median follow-up of 4.8 years; 46 patients (15 percent) developed incident cancers (25 new; 21 recurrent). The crude rate of incident cancer was 2.58 and 4.78 out of 100 person-years in unexposed and immunosuppression-exposed patients, respectively (relative risk, 1.85; 95 percent confidence interval, 0.92 to 3.73). No significant association was seen between receipt of immunosuppression and incident cancer or with any major drug class after adjustment for sex, smoking history, age and stage at index malignancy, and nonmelanoma skin cancer.
"We did not find significant associations between subsequent exposure to immunosuppressive IBD therapies and development of incident cancer after adjusting for various demographic and clinical characteristics," the authors write.
Several authors disclosed ties to the pharmaceutical and diagnostics industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Estimated U.S. Annual Cost of Initial Cancer Screening $43 Billion in 2021
MONDAY, Aug. 5, 2024 -- In 2021, the estimated total health care costs for initial cancer screening were $43 billion in the United States, according to a study published online...
Study Compares Surgical Techniques for Crohn Disease
THURSDAY, Aug. 1, 2024 -- For patients undergoing open or laparoscopic resection of the small bowel or strictureplasty for Crohn disease (CD), small bowel resection is associated...
Incidence of Many Cancers Increasing Among Younger Generations
THURSDAY, Aug. 1, 2024 -- Younger birth cohorts have an increased incidence of many common cancer types, according to a study published in the August issue of The Lancet Public...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of drugclasses.com in your inbox.